Zymeworks, Inc. (ZYME)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$27.15-3.42%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Achieve ~80% revenue growth in 2026: rev -90.6% vs 80%.
Zymeworks is cutting costs by about 20% in 2026 to improve its finances. It has a $125 million share buyback program backed by a stronger balance sheet. The company completed a $929 million acquisition to support growth and capital needs. Analysts expect revenue to grow about 80% next year.
Zymeworks is still loss-making and has missed earnings multiple times in 2026. Its profit outlook is weak with EPS expected to fall next year. The company faces volatile management and elevated risk. Cost cuts may not be enough to reach profitability soon.
The stock price is about 2.5% above our fair value near $28, reflecting roughly 80% revenue growth expected by analysts. Our fair value is 32% below the Street median, indicating some skepticism about the company’s turnaround. We see risk in earnings and cash flow recovery.
Breaks if: no meaningful share repurchases executed by end of 2026
Breaks if: adjusted gross operating expenses do not decline by at least 15% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity. ZYME is currently loss-making with weak recent financial performance, but it is focused on advancing regulatory approvals and integrating new assets from an acquisition.
The market seems to have priced in a significant expectations gap, indicating that investors may not fully believe in the company's ability to execute on its plans. ZYME is trading at a premium compared to peers, reflecting some optimism despite its recent struggles.
Fundamentally, ZYME is at risk of missing earnings again, as it has a high probability of doing so based on recent performance. However, management is on track with its priorities, which could stabilize the business if executed well.
The long-term thesis hinges on the successful advancement of regulatory approvals for zanidatamab and the integration of Theravance Biopharma. Additionally, broader market conditions and sector performance will play a critical role in ZYME's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. H.C. Wainwright raised its revenue estimate to $55. This suggests higher revenue for Ziihera in gastroesophageal adenocarcinoma. The company missed earnings expectations recently, which is a concern. It also faces pressure from its acquisition strategy.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue disciplined cost management to lower adjusted gross operating expenses by approximately 20% in 2026 versus 2025.
Breaks if: revenue growth falls below 50% in FY26
Breaks if: strategic acquisition or partnership fails to close or provide expected capital support
Over the next 1 to 3 years, ZYME's outlook will depend heavily on execution and external market factors. Not investment advice.